The EXPLORE44 study enrolled DMD patients with DMD mutations amenable to exon 44 skipping (DMD44), a group that accounts for around 6% of all DMD cases in the US. It showed a statistically ...

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

At close: 11 April at 16:00:00 GMT-4 ...